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Abstract
Factor XIII deficiency (FXIIID) is an extremely rare hemorrhagic disorder with a 
prevalence of 1/3-5 million. Management of disease is performed by fresh frozen plasma 
(FFP), Cryoprecipitate (CP) or FXIII concentrate (Fibrogammin P®). Our objective was to 
assess safety and effectiveness of Fibrogammin P® in patients with FXIIID. For this purpose 
we designed this long-term follow up study on a large group of patients with FXIIID.
This prospective study was conducted on 213 patients with FXIIID since 2009 to 2013. 
Administrated dose for Fibrogammin P® according to clinical situations of patients ranged 
from 10 to 26 IU/kg every 4-6 weeks. All patients in 6-month intervals were checked for human 
immunodeficiency virus (HIV), hepatitis A, B and C viruses (HAV, HBV, HCV).
Twelve percent of participants had at least one ICH episode until 2008 but after administration 
of Fibrogammin P® did not have any major bleeding or episode of ICH, except in one patient. 
We also had 7 females with recurrent miscarriage that were managed successfully with a dose 
of 10 to 26 IU/kg every 4-6 weeks. This dose also was quite successful in management of 
major and minor surgery. None of the participants showed allergic reaction during treatment. A 
total of 7155450 IU of Fibrogammin P® were infused but nobody was positive for HIV, HAV, 
HBV, and HCV. We found that Fibrogammin P® is a safe and effective therapeutic choice in 
management of FXIIID.
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Introduction
Coagulation factor XIII (FXIII) is a fibrin-
stabilizing transglutaminase consisting of 
catalytic A subunits (FXIII-A) and carrier B 
subunits (FXIII-B). FXIII strengthens fibrin 
clot mechanically by cross-linking fibrin chains 
and also protects newly formed fibrin from 
the activated fibrinolytic system by binding 
α
2
-plasmin inhibitor to the fibrin meshwork. 
Congenital FXIIID is a rare but severe and 
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potentially life-threatening autosomal 
recessive bleeding disorder with a prevalence 
of one in 3–5 million people and affects 
people from all races and ethnics (1-3). The 
prevalence of the FXIIID in Iran, with about 
473 patients, is 12-fold higher than the global 
frequency (1, 2). There is often a history of 
consanguinity within certain families of FXIII 
deficient patients. The disorder is associated 
with severe hemorrhage, spontaneous central 
nervous system (CNS) bleeding, spontaneous 
miscarriage, delayed wound healing and 
umbilical bleeding which presents a few days 
after birth. Patients with severe innate FXIIID 
usually present with plasma FXIII levels less 
than 1% and severe hemorrhagic episodes (3, 
5). Due to the risk of ICH and other severe 
bleeding episodes, most patients receive 
regular prophylaxis replacement therapy. Due 
to the risk of blood born diseases, FFP and CP 
are less satisfactory for on-demand treatment 
or prophylaxis and FXIII concentrate is 
recommended whenever available (2-5). Half-
life of FXIII is the longest among coagulation 
factors and it has been suggested that serum 
factor levels around 2-5% are sufficient to 
prevent spontaneous bleeding and to avoid the 
risk of early fetal loss (1-3). 
FXIII replacement by Fibrogammin P®, a 
highly purified pasteurized (at 60 ºC for 10 h) 
FXIII concentrate which derived from HIV-
negative, pooled human plasma screened for 
common viruses, is used to treat hemorrhage, to 
prevent perioperative bleeding during elective 
operating procedures, or prophylactically to 
prevent recurrent bleeding (6-8). High rate 
of consanguineous marriage in Sistan and 
Baluchestan Province of Iran leads to increased 
prevalence of disorders which inherited in 
autosomal recessive pattern (1). It seems that the 
province has the largest population of patients 
with severe FXIIID around the world and these 
patients are available for long-term follow-up 
and there is no published evidence on the safety 
and efficacy of Fibrogammin P®. Of course this 
disease is also seen in other provinces such as 
Fars, and a total number of 8 patients are already 
registered in this province. Fibrogammin has 
been available since 2009 in Iran. The aim 
of this prospective study was to evaluate the 
tolerance, efficacy and safety of Fibrogammin 
P® (CSL-Behring, Marburg, Germany) for the 
management of patients with severe inherited 
FXIIID in Iran.
Experimental
Study design 
For investigation of safety and effectiveness 
of Fibrogammin P®, we designed this 
prospective study, based on long term follow 
up of a large group of FXIIID patients receiving 
this product. The key elements in performing the 
study included determination of characteristics 
of study population at baseline, then assessment 
of clinical presentations among patients in each 
referral and finally assessment of safety and 
efficacy of prophylaxis treatment. 
Characteristics of study population
This prospective study was conducted on 
213 patients with severe FXIIID. Patients 
gave their written consent and the study was 
approved by the medical ethics committee of 
Zahedan and Shiraz Universities of Medical 
Sciences. Demographic data and previous 
medical history of all patients including age, 
gender, family history of bleeding disorders, 
and bleeding events was obtained from their 
medical files or by interview. Recorded database 
of patients with congenital FXIIID who were 
regularly referred to the referral hospitals and 
received Fibrogammin P® prophylactically 
since 2009 to 2013 was prospectively captured. 
Patients who had incomplete medical history, 
blood viral infection, and patients received 
prophylactic FFP or CP during the study were 
excluded. 
Screening and diagnosis of FXIIID
Diagnosis of the disease was based 
on clot solubility test, family history and 
clinical presentations. Once a case referred 
to our hemophilia centers with hemorrhagic 
complications or a new born baby with positive 
family history of any bleeding disorder or 
hereditary coagulation factor deficiencies and 
accompanied by normal results of screening 
clotting tests, their samples underwent FXIII 
screening test (9). 
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Assessment of clinical bleeding episodes 
After diagnosis of severe FXIIID, patients 
underwent prophylaxis or on-demand treatment 
in special conditions such as CNS bleeding, 
pregnancy, surgery and dental procedures. 
Administrated dose for Fibrogammin P® 
was based on clinical situation of patients. 
Administrated dose, duration of treatment, 
bleeding episodes, usage of parallel therapeutic 
agents and adverse events in the previous five 
years was recorded for each patient. Bleeding 
episodes of each patient at the baseline, and 
after each referral to receive prophylactic 
treatment during the 5 years of follow up 
were recorded. In our assessment epistaxis 
was defined as positive only when occurred 
spontaneously, from both nostrils, and did not 
stop with compression, lasted more than 10 
min or medical intervention was inevitable. 
Post-surgery or circumcision hemorrhage was 
defined as positive when happened without 
trauma.
 Due to high rate of bleeding episodes in 
severely deficient patients and the risk of CNS 
bleeding leading to death, there is no control 
group. Therefore historical records of bleeding 
episodes were used to compare bleeding 
frequencies prior to and during Fibrogammin 
P® prophylaxis. 
Assessment of safety and efficacy of 
prophylaxis treatment 
An adverse event was defined as any 
unexpected or critical symptom, sign, or 
laboratory finding temporally associated with 
Fibrogammin P® infusion regardless of causal 
relationship. A serious adverse event was 
defined as any untoward medical occurrence 
that resulted in life threatening and prolonged 
existing hospital care, or that resulted in 
significant disability or patients’ death. Adverse 
events documented for this study were those 
that occurred within five years of Fibrogammin 
P® administration. Patients were also regularly 
(every 6 months) checked up for viral diseases 
including, HIV, HBV, HAV and HCV. 
Data analysis was done by SPSS v. 17 
(SPSS Inc., Chicago, IL, USA). We used mean 
and range for indicating the age of patients 
and percentage for showing the frequency of 
descriptive variables such as gender and clinical 
manifestations.
Results
Characteristics of subjects
The study involved 213 patients with severe 
FXIIID including 103 (48.4%) males and 110 
(51.6%) females, which received Fibrogammin 
Table 1. Frequency of clinical presentations in the studied population before administration of Fibrogammin P® (in each gender and in 
total patients).
                      Clinical
 presentation
Female
(n)%
Male
(n)%
Total
(n)%
Umbilical bleeding (88) 80% (90) 87% (178) 84%
Deep soft tissue Hematoma (52) 47% (56) 54% (108) 51%
Prolonged wound Bleeding (29) 26% (32) 31% (61) 29%
Intracranial bleeding (10) 9% (15) 15% (25) 12%
Gum bleeding (22) 20% (16) 15% (18)18%
Ecchymosis  (19)17% (17)16.5% (36) 17%
Epistaxis (21)19% (17) 16.5% (38) 18%
Delayed post dental extraction 
bleeding
(10) 9%  (9) 9% (19) 9%
Miscarriage (7) 6% - (7) 3%
Post circumcision bleeding - (6) 6% (6) 3%
Hemarthrose (5) 5% (3) 3% (8) 4%
Post-surgical bleeding (2) 2% (4) 4% (6) 3%
Prolonged menstrual bleeding (1) 1% - (1) 0.5%
Subcutaneous bleeding (2) 2% (1) 1% (3) 1.5%
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P® at least once during 5 years of study. The 
mean age of patients was 18.5 years (range, 1 
year to 44 years). A positive family history 
was found in 74 patients (about 35%) with 
FXIIID. One patient had factor VII deficiency 
simultaneously with FXIII deficiency. 
Clinical manifestations
ICH was the primary bleeding episode leading 
to detection of FXIIID in about 12% of patients 
(15 males and 10 females). The most frequent 
symptom among our patients was umbilical 
cord bleeding (84%). All the bleeding events 
of the studied population which was detected 
at baseline are indicated in table 1. Prospective 
study on these patients revealed that some clinical 
manifestations such as epistaxis and deep soft 
tissue hematoma occurred several times in most 
patients and they experienced these phenomena 
more than once. However intracranial bleeding 
occurred just once in the majority of patients 
which experienced this complication. ICH was 
the main cause of hospitalization and the first 
fatal presentation among our FXIII deficient 
patients. The areas involved were occipital, 
frontal and parietal. The mean age of ICH was 
3.5 years old (minimum 7 months and maximum 
42 years). We also had mental retardation and 
dysphasia in three patients.
Safety and efficacy outcomes 
During the five years of study, the average 
administrated dose of Fibrogammin P® for 
prophylaxis treatment was 10 to 26 IU/kg every 
4 – 6 weeks. Moreover on-demand therapy with 
required dose in 25 patients in special situations 
such as major bleeding episodes, surgery and 
delivery was another treatment regimen. The 
main manifestations of the study population, 
before and after administration of Fibrogammin 
P® are compared in Table 2. 
None of the participants showed allergic 
reaction attributable to Fibrogammin P® infusion 
during treatment period.A total of 7155450 IU of 
Fibrogammin P® were infused during the time 
of study but our regular follow-up and periodic 
serological evaluations of HIV, HAV, HBV and 
HCV showed negative results for all patients.
Discussion
Current replacement therapy of FXIIID 
is limited to CP, FFP and FXIII concentrate 
(1, 2). This prospective study reporting a long 
time follow-up among patients with severe 
FXIIID, receiving FXIII replacement therapy 
with Fibrogammin P®, a highly purified virus 
inactivated plasma derived FXIII concentrate. 
Fibrogammin P® appears to carry low and 
negligible risk of viral transmission, unlike other 
unprocessed products containing FXIII (6-8). 
Published evidence on the safety or efficacy of 
Fibrogammin P® therapy mainly includes case 
reports, retrospective surveys or small series (6-
8, 10, 11). In a retrospective study by Lusher et 
al. on seven subjects with congenital FXIIID 
receiving only Fibrogammin P® in a period of 
one year, it was revealed that the frequency of 
spontaneous bleeding events was significantly 
lower during prophylaxis with Fibrogammin P® 
Table 2. Comparison of the major clinical presentations in the studied population, before and after administration of Fibrogammin P®.
After administration of Fibrogammin P®Before administration of Fibrogammin P®
No major bleeding event was observed except 
hematoma which was detected in few cases. 
Mainly minor bleedings such as epistaxis and gum 
bleeding were observed
Major bleeding events such as umbilical bleeding 
(84%), hematoma (51%), ICH (12%), and 
miscarriage (6%of females) were detected among 
patients
General manifestations
No episode of ICH or other major bleeding events 
was occurred, except in one who experienced ICH 
despite prophylaxis (14) 
At least one ICH episode was observed in 12% of 
patients ICH
No fetal loss was observed and patients had 
successful pregnancies 
Seven females had experienced recurrent 
miscarriages
Recurrent miscarriage
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than prior of this regimen (p=0.01) (6). Another 
study reported by Dreyfus et al. on 19 severely 
FXIII deficient patients also resulted in a good 
or excellent efficacy of Fibrogammin P® in 95% 
of cases in duration of 12 months follow up. 
They also introduced Fibrogammin P® as a safe 
product (7). Although the same findings were 
obtained in our study, but it must be considered 
that we enrolled a large number of patients 
and followed them for a long period (5 years), 
which may lead to more reliable and accurate 
results. However in such studies, missing the 
subjects during the long time of follow up due 
to lack of cooperation, inappropriate referral 
intervals or even death of the patients, is a major 
limitation. Previously we had assessed safety of 
human blood products in rare bleeding disorders 
(RBDs) in a long period study and found that 
FFP and CP were safe in treatment of RBDs 
(12). This study was conducted pursuant to the 
previous study on a large group of patients with 
RBDs. FXIII deficient patients are the biggest 
group of patients with RBDs in southeast of 
Iran and comprise 78.6 % of all patients with 
RBDs (12). This large group of patients had a 
wide spectrum of clinical presentations. Like 
previous studies umbilical cord bleeding was the 
most common clinical presentation (5, 13). ICH 
was other common clinical manifestation which 
led to high rate of morbidity and mortality (14, 
15). Among study patients with ICH, a positive 
history of death was observed in 72 percent (18 
individuals). The most common cause of death 
among these individuals was CNS bleeding (61 
%). Out of 11 deaths, 8 cases were because of 
FXIIID.  The remaining three patients were 
suspected to FXIIID. These individuals were 
not diagnosed as FXIIID because they did not 
refer to physician for diagnosis of their disorder, 
but based of clinical presentations which stated 
by their parents and also because of positive 
family history and CNS bleeding was suspected 
to FXIIID. This high rate of morbidity and 
mortality in patients with FXIIID makes CNS 
bleeding our main concern. These patients were 
managed successfully by a dose of 10-26 IU/Kg 
of Fibrogammin P®. This dose was completely 
successful in the management of these patients, 
and prevented occurrence of ICH in all patients 
except in one. This patient was received up 
to 26 IU/Kg of Fibrogammin P® but even 
this relatively high dose was not sufficient for 
prevention of recurrent ICH. Genetic risk factors 
are important causes of therapeutic response. 
We previously assessed the relationship between 
genetic risk factors and occurrence of ICH (15). 
We found a strong relationship between TAFI 
Thr325Ile polymorphism and risk of ICH. In 
that study we had a patient with inappropriate 
therapeutic response to prophylaxis treatment 
which was homozygote for TAFI Thr325Ile 
polymorphism (15). We also managed our 
patients with miscarriage by Fibrogammin P® 
in a dose of 10-26 IU/Kg. Out of seven patients 
with miscarriage; one had experienced this 
phenomenon 11 times but after administration 
of Fibrogammin P® in a dose of 20 IU/Kg had 
experienced a successful delivery. 
Allergic reaction was other complication of 
human plasma derived products but no allergic 
reaction was observed during or after infusion 
of Fibrogammin P®, and the concentrate was 
well tolerated without untoward side-effects. 
We previously assessed occurrence of allergic 
reaction in patients with FXIIID treated 
prophylactically with FFP and CP, and did not 
observe any allergic reaction (12). It seems that 
allergic reaction is not a usual complication 
among the recipients of plasma derivative 
components. Our present study also confirmed 
it and we did not observe any allergic reaction 
in patients received Fibrogammin P® as plasma 
derived concentrate.  
Moreover during time of study our patients 
were checked up at regular intervals of six 
months for HIV, HCV, HAV and HBV.  Lack 
of transfusion-related viral infection after 
administration of 7155450 IU of Fibrogammin 
P® shows the safety of plasma-derived FXIII 
concentrate in management of FXIIID. These 
results are in accordance with those of previous 
small series in other countries such as USA and 
France (6-8, 10, 16). A short term study by Diane 
Nugent et al on 41 patients with congenital FXIIID 
confirms our data. They found Fibrogammin as 
an effective therapeutic choice in management 
of congenital FXIIID. They also did not find any 
viral transmitted disease among their patients 
(16). Like our study, Diane Nugent et al found 
Fibrogammin an effective therapeutic choice in 
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management of major bleeding episodes, surgery 
and delivery (16). 
The result of this study revealed that 
Fibrogammin P® is a safe and also an effective 
therapeutic choice in management of severe 
FXIIID.
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